6533b82afe1ef96bd128cbc4
RESEARCH PRODUCT
Quality of Life Following Prestige LP Cervical Disc Arthroplasty in a Prospective Multicountry Study
Marton RonaiJiri MatejkaDariusz LatkaDaniel ZarzyckiBruno RudinskyJan StulikSaleh S. Baeesasubject
medicine.medical_specialtymedicine.medical_treatmentcervical spineDegenerative disc disease03 medical and health sciences0302 clinical medicineQuality of lifeBlood lossmedicineOrthopedics and Sports MedicineAdverse effect030222 orthopedicsbusiness.industrymedicine.diseaseArthroplastySurgeryPrestige LP Cervical Discquality of lifedegenerative disc diseasearthroplastySurgeryObservational studybusinessCervical discBody mass index030217 neurology & neurosurgerydescription
BACKGROUND: To describe routine surgical practice using Prestige LP Cervical Disc (Prestige disc) and patient outcomes for degenerative cervical disc disease in a multicenter 2-year prospective, observational study. METHODS: Patient demographics and intraoperative data were collected; quality of life (QoL) (EQ-5D, EQ-VAS, and neck disability index), average disc height, and adverse events were assessed pre- and postoperatively at 3, 6, 12, and 24 months. RESULTS: One hundred and ninety-four patients were enrolled (190 patients implanted; female: 67%; mean age: 44.0 years; mean body mass index: 25.6). Disc herniation was the most frequent indication for cervical arthroplasty (80.5%). Thirty-seven percent of patients experienced pain for >1 year prior to baseline assessment. Mean procedure duration was 87.1 minutes, and mean blood loss was 43.8 mL. The majority (71.0%) of Prestige discs were implanted at level C5 to C6, while 16.3% of patients received implants at 2 levels. There was a significant improvement from baseline to 3, 6, 12, and 24 months of follow-up in all QoL assessments. After implantation, the mean disc height at the affected level increased by 0.19 from baseline (0.22) to 3 months (0.41) and remained constant up to 24 months (P < .001). Mean disc height of levels above and below the implant remained comparable at baseline and follow-up. A total of 63 adverse events (44 patients) was recorded, of which 7 (11.1%) were related to the Prestige disc, instrumentation, or procedure; 41 (65.1%) were unrelated; and 15 (23.8%) had an unknown relation. CONCLUSIONS: In line with published findings, our study shows significant improvement in outcomes in the first 3 months after Prestige disc implantation with improvements maintained throughout the study.
year | journal | country | edition | language |
---|---|---|---|---|
2019-06-01 | International Journal of Spine Surgery |